Successful Completion of Phase I Clinical Study of SK08
Release Time: 2021-01-13
Recently, a Phase I clinical study met its primary objective of demonstrating safety and tolerability of SK08（Bacteroides fragilis）in Guangdong Provincial People’s Hospital, which was a single-center, randomized, placebo-controlled, double-blinded study conducted in healthy volunteers. This study included single drug resistance test and multiple drug resistance test. No serious drug-related adverse events were observed, the final report of the clinical study concludes that SK08 is safe.
SK08 now has started the preliminary work of Phase II clinical trial and plans to enrollment in the first half of 2021.